Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...

Please provide your email address to receive an email when new articles are posted on . People with narcolepsy were more likely to develop heart disease than propensity score-matched people without ...

Narcolepsy was linked to high blood pressure, hyperlipidemia, and diabetes on top of outright cardiovascular disease events in a retrospective cohort study. Notably, patients with narcolepsy started ...

Narcolepsy is estimated to affect one in 2,000 people in the United States and some 3 million worldwide, according to the Narcolepsy Network, a non-profit patient advocacy group. However, that ...

The US Food and Drug Administration (FDA) has approved Avadel Pharmaceuticals’ supplemental new drug application for extended-release sodium oxybate (Lumryz) for treatment of cataplexy or excessive ...

"Our findings show that the schizophrenia diagnosis in narcoleptic patients is a phenomenon that does not occur only by chance but also having NT1 can be considered as a risk factor for developing ...

How Does Sunosi Treat Sleepiness? People with obstructive sleep apnea (OSA) or narcolepsy can feel very sleepy during the daytime. This medicine helps you feel more awake. It increases the levels of ...

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), ...

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.

(CNN) — Matthew Horsnell began falling asleep for no reason when he was in sixth grade. “I would go to bed at 8:30 at night, yet every morning I would wake up and struggle to get out of bed,” said ...